Literature DB >> 31802403

Comment on "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Yang Yu1,2, Marc Maliepaard3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31802403     DOI： 10.1007/s40262-019-00850-5

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  8 in total

1.  Some statistical considerations on the FDA draft guidance for individual bioequivalence.

Authors:  F C Hsuan
Journal:  Stat Med       Date:  2000-10-30       Impact factor: 2.373

2.  Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence.

Authors:  L Endrenyi; N Taback; L Tothfalusi
Journal:  Stat Med       Date:  2000-10-30       Impact factor: 2.373

3.  A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.

Authors:  Yang Yu; Steven Teerenstra; Cees Neef; David Burger; Marc Maliepaard
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

4.  Medicine and the Media. Thyroxine: anatomy of a health scare.

Authors:  Kate Faasse; Tim Cundy; Keith J Petrie
Journal:  BMJ       Date:  2009-12-29

5.  Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.

Authors:  Rodrigo Cristofoletti; Malcolm Rowland; Lawrence J Lesko; Henning Blume; Amin Rostami-Hodjegan; Jennifer B Dressman
Journal:  J Pharm Sci       Date:  2018-06-20       Impact factor: 3.534

6.  Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study.

Authors:  P Saravanan; W-F Chau; N Roberts; K Vedhara; R Greenwood; C M Dayan
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

7.  Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?

Authors:  Didier Concordet; Peggy Gandia; Jean-Louis Montastruc; Alain Bousquet-Mélou; Peter Lees; Aude Ferran; Pierre-Louis Toutain
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 8.  Requirements for generic anti-epileptic medicines: a regulatory perspective.

Authors:  Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.